# The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps

> **NCT06015243** · PHASE2 · UNKNOWN · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Chronic Rhinosinusitis With Nasal Polyps

## Interventions

- **DRUG:** GR1802 injection

## Key facts

- **NCT ID:** NCT06015243
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-18
- **Primary completion:** 2024-12-30
- **Final completion:** 2025-03-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06015243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06015243, "The Study of Long-term Outcomes of GR1802 in Patients With Chronic Rhinosinusitis With Nasal Polyps". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06015243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*